Recent news items are listed chronologically below. To view our archive of older news items please click here

 

To subscribe to our RSS news feed and thereby be automatically upated with changes to this page in your feed reader of choice, please click the orange icon to the right.

 

Sygnature to Support Wellcome-funded Pneumococcal Diseases Project 20 May 2010 Sygnature Chemical Services Ltd. has been selected by the University of Leicester to support a Wellcome Trust Seeding Drug Discovery Initiative (SDDI)-funded research programme to identify new treatments for invasive pneumococcal diseases.

Sygnature is recruiting. 20 April 2010 Sygnature is looking for innovative and enthusiastic synthetic Research Chemists and an Analytical Support Chemist to join our research teams in Nottingham.

Sygnature Strengthens Scientific Team. 21 January 2010 Sygnature today announced the appointment of Dr Michael Knaggs as Head of Computational Chemistry.

Sygnature and Cyprotex Establish Strategic Alliance 09 December 2009 Sygnature Chemical Services Ltd. and Cyprotex Discovery Ltd. have announced they have entered a strategic alliance in order to provide a fully integrated discovery chemistry/DMPK service.

Successful Collaboration with RespiVert 17 November 2009 Sygnature and RespiVert yesterday provided an update on their research collaboration aimed at identifying novel therapeutic agents for the treatment of poorly controlled, steroid refractory pulmonary disease.

Chemistry Collaboration with Heptares 08 October 2009 Sygnature Chemical Services Ltd. and Heptares Therapeutics Ltd. have started working together to advance one of Heptares’ internal high-value GPCR programmes.

Sygnature Awarded Investment Grant 28 July 2009 Sygnature Chemical Services Ltd has been awarded a £390,000 Grant for Business Investment (GBI) award by the East Midlands Development Agency (emda) and the European Regional Development Fund (ERDF).

Sygnature expands flow chemistry capabilities. 15 April 2009 Sygnature has recently added the FlowSyn TM continuous flow reactor from UNIQSIS to its technology capability and is the first CRO in the UK to invest in the UNIQSIS system.

Sygnature announces new appointments to the Board of Directors 08 April 2009 Dr Jonathan Williams becomes Director of Operations. Dr Paul Clewlow has joined Sygnature as Senior Vice-President, Business Development.

Sygnature extends its research facilities 08 April 2009 Due to an unprecedented demand for it's contract medicinal chemistry services, Sygnature has already outgrown the purpose-designed and built laboratory and office space occupied during the £1m expansion announced in April 2008, and expanded into additional space within BioCity's state-of-the-art Laurus building.

Sygnature to exhibit at Drug Discovery Chemistry conference 08 April 2009 Sygnature is participating in the Drug Discovery Chemistry conference, San Diego, in April 09 to showcase it's medicinal and synthetic chemistry expertise.

Sygnature sponsors Compound Libraries 2008 25 June 2008 Sygnature is sponsoring this years Compound Library meeting in Düsseldorf, Germany, 6th-8th October 2008.  CEO, Dr Simon Hirst will be presenting Sygnature's approach to Hit-to-lead chemistry under the expanded remit of the conference which now covers library design and Hit-to-lead optimization.